Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

Announcement Under Regulation 30 (LODR)- Updates

 Subject: Transfer of Company''s Active Pharmaceuticals Ingredient (API) Business. Further to the earlier intimation dated September 25, 2018, announcing the shareholder approval for the above transaction, we hereby advise that a Business Purchase Agreement for transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company, has been executed on October 9, 2018. The transaction is expected to be completed in the next 2-3 months.
09-10-2018
Bigul

Shareholding for the Period Ended September 30, 2018

 Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here
08-10-2018
Bigul

Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2018.

 Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 30th September, 2018.
08-10-2018
Bigul

Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2018.

 Enclosed please find herewith the Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 30th September, 2018.
04-10-2018
Bigul

Statement Of Investor Complaints For The Quarter Ended September 2018

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 041410 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer
04-10-2018
Bigul

ANNOUNCEMENT OF RESULTS OF THE REPURCHASE AS AT THE EXPIRATION TIME IN RESPECT OF THE COMPANY'S U.S.$200,000,000 2.00 PER CENT. RESETTABLE ONWARD STARTING EQUITY-LINKED SECURITIES DUE 2022

 With respect to the above subject, please find enclosed herewith Announcement of Results of the Repurchase. You are requested to take the same on record.
03-10-2018
Bigul

Update On Intimation Regarding The Orthopaedic Business

 Reference is made to the intimation made to the Stock exchanges on August 10, 2018 by the Company in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, about the approval of the Board for the transaction with True North for Orthopaedic and Pain Management Business. We now wish to inform you that the Company has completed the formalities. You are requested to take the same on record.
01-10-2018
Bigul

Intimation Of Proposed Cash Buyback In Respect Of Glenmark Pharmaceuticals Limited ('Company') Of Its U.S.$200 Million 2 Per Cent Resettable Onward Starting Equity Linked Securities Due 28 June 2022 ('FCC Bonds')

 This is further to our letters dated 25 September 2018 and dated 28 September 2018 regarding a buyback of FCC Bonds issued in 2016 which are currently listed on the Singapore Exchange Securities Trading Limited ('SGX-ST'). The Board of Directors of the Company delegated powers to the operations committee. The operations committee approved the launch of buyback of FCC Bonds ('Buyback FCCBs') from existing holders of FCC Bonds ('Buyback Bondholders')...
01-10-2018
Bigul

Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
01-10-2018
Bigul

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 Proceedings and Scrutinizer''''s Report of the 40th Annual General Meeting {AGM) of Glenmark Pharmaceuticals Limited (''''the Company'''') held on September 28, 2018
28-09-2018
Next Page
Close

Let's Open Free Demat Account